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Excitotoxic stimulus stabilizes PFKFB3 causing
pentose-phosphate pathway to glycolysis switch
and neurodegeneration
P Rodriguez-Rodriguez1, E Fernandez1, A Almeida1,2 and JP Bolan˜os*,1
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is a master regulator of glycolysis by its ability to synthesize
fructose-2,6-bisphosphate, a potent allosteric activator of 6-phosphofructo-1-kinase. Being a substrate of the E3 ubiquitin ligase
anaphase-promoting complex-Cdh1 (APCCdh1), PFKFB3 is targeted to proteasomal degradation in neurons. Here, we show that
activation of N-methyl-D-aspartate subtype of glutamate receptors (NMDAR) stabilized PFKFB3 protein in cortical neurons.
Expressed PFKFB3 was found to be mainly localized in the nucleus, where it is subjected to degradation; however, expression of
PFKFB3 lacking the APCCdh1-targeting KEN motif, or following NMDAR stimulation, promoted accumulation of PFKFB3 and its
release from the nucleus to the cytosol through an excess Cdh1-inhibitable process. NMDAR-mediated increase in PFKFB3
yielded neurons having a higher glycolysis and lower pentose-phosphate pathway (PPP); this led to oxidative stress and
apoptotic neuronal death that was counteracted by overexpressing glucose-6-phosphate dehydrogenase, the rate-limiting
enzyme of the PPP. Furthermore, expression of the mutant form of PFKFB3 lacking the KEN motif was sufficient to trigger
oxidative stress and apoptotic death of neurons. These results reveal that, by inhibition of APCCdh1, glutamate receptors
activation stabilizes PFKFB3 thus switching neuronal metabolism leading to oxidative damage and neurodegeneration.
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In contrast to the neuroprotective actions of mild glutamatergic
synaptic activity,1 persistent activation of the N-methyl-D-
aspartate subtype of glutamate receptors (NMDAR) – including
the extra-synaptic ones2 – is known to underlie the patho-
genesis of a number of neurological disorders, including
Alzheimer’s disease, amyotrophic lateral sclerosis or stroke.3
This phenomenon, known as excitotoxicity, causes neuronal
apoptotic death through a not yet fully understood mechanism,
but it is thought to involve an increase in intracellular Ca2þ
through NMDAR, followed by plasma membrane depolari-
zation and, hence, opening of voltage-gated Ca2þ channels,
release from intracellular stores and reversal of the plasma
membrane Naþ /Ca2þ exchanger.4 This process eventually
triggers the accumulation of mitochondrial Ca2þ , leading
to increased reactive oxygen species (ROS) formation,
mitochondrial energy dysfunction, permeability transition pore
opening and cytochrome c release.5 Besides mitochondria,
it has also been recently shown that cytoplasmic NADPH
oxidase has a key role in ROS production upon NMDAR
stimulation.6 Thus, Ca2þ influx activates protein kinase C,
which in turn phosphorylates and activates p47phox; p47phox
coordinates NAPDH oxidase subunit organization, leading
to enzyme activation.6 Regardless the origin of ROS, it is
thought that neurons are highly vulnerable to mitochondrial
stress, likely because of their inability to sufficiently activate
glycolysis and, hence, to transiently compensate energy
deficiency.7,8 In contrast to neurons, astrocytes and other
proliferative cells readily invoke glycolysis as a cytoprotective
mechanism.8–11
Glycolysis is controlled by the activity of 6-phosphofructo-
1-kinase, the activity of which is highly dependent on its
potent allosteric activator, fructose-2,6-bisphosphate (F2,6P2);
in the brain, F2,6P2 biosynthesis almost exclusively relies
on 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFKFB3) activity.12,13 Previously, we reported that the
inability of neurons to promote cytoprotective glycolysis is
because of the virtual absence of PFKFB3.14 Furthermore,
we recently found that PFKFB3, through its KEN motif, is a
substrate of the E3 ubiquitin ligase, anaphase-promoting
complex (APC)-Cdh1 (APCCdh1),15 which accounts for the
high instability of PFKFB3 and low glycolytic rate in neurons.15
Inhibition of APCCdh1 in postmitotic neurons triggers an
accumulation of its substrate, cyclin B1, which mediates
apoptotic death.16 Moreover, cyclin B1 accumulation can also
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be recapitulated by NMDAR stimulation, which activates
cyclin-dependent kinase 5 (Cdk5)-mediated Cdh1 phosphor-
ylation, leading to APCCdh1 inhibition.17 In view of the control
that APCCdh1 exerts over PFKFB3 stability,15 here we hypo-
thesized whether NMDAR stimulation, via APCCdh1 inhibition,17
regulates PFKFB3 protein levels in neurons. We show that
NMDAR activation, through inhibition of APCCdh1 caused
PFKFB3 stabilization leading to increased glycolysis and
reduced activity of the pentose-phosphate pathway (PPP). This
metabolic alteration triggered oxidative damage and excitotoxic
neuronal death, thus suggesting that modulators of neuronal
energy metabolism should be considered as targets in
therapeutic strategies against neurodegenerative diseases.
Results
In order to test whether rat primary cortical neurons in culture
responded to glutamate receptor activation, we first monitor-
ized the changes in Fura-2 fluorescence. As shown in
Figure 1a, Fura-2 F335/F363 ratio – an index of intracellular
Ca2þ levels – increased by B1.3-fold immediately after the
addition of glutamate (100 mM) or N-methyl-D-aspartate
(NMDA; 100mM). Furthermore, pre-incubation of neurons
with the NMDAR antagonist, MK801 (10mM), prevented by
B60% glutamate-mediated increase in F335/F363 ratio
(Figure 1a, left panel); MK801 almost abolished (by B90%)
NMDA-mediated increase in F335/F363 ratio (Figure 1a, right
panel). These results suggest that, under our experimental
conditions – cells grown in serum-based medium – cortical
neurons express functional NMDAR and, hence, are useful for
the study of excitotoxic-mediated metabolic changes. To
investigate whether glutamate receptor activation controls
PFKFB3 stability, we then incubated neurons with glutamate
(100 mM/15 min), and the levels of PFKFB3 protein were
analyzed by western blotting. As shown in Figure 1b,
glutamate triggered a time-dependent increase in PFKFB3,
an effect that was maximal (by B2.1-fold) after 6 h. To see
whether this effect was mediated by NMDAR, neurons were
incubated with NMDA (100 mM/15 min), and PFKFB3 protein
levels analyzed 6 h later. As depicted in Figure 1c, NMDA
mimicked glutamate at increasing PFKFB3. Moreover, incu-
bation of neurons with MK801 prevented glutamate-mediated
increase in PFKFB3 (Figure 1d). Glutamate did not alter
PFKFB3 mRNA levels (Figure 1e). These results suggest that
activation of NMDAR stabilizes PFKFB3 protein in neurons.
Next, we investigated the involvement of APCCdh1 activity in
determining PFKFB3 stabilization by NMDAR. In view that
NMDAR activation promotes APCCdh1 inhibition by Cdk5-
mediated phosphorylation of Cdh1,17 we tested whether this
observation could be confirmed in our conditions. As shown in
Figure 2a, glutamate (100 mM/15 min) promoted, after 4 h, H1
phosphorylation in neuronal samples immunoprecipitated
with anti-Cdk5; furthermore, this effect was prevented by
MK801, suggesting NMDAR-mediated activation of Cdk5
activity. In addition, Cdh1 was phosphorylated – suggesting
APCCdh1 inhibition – 6 h after glutamate treatment, an effect
that was also prevented by MK801 (Figure 2b). To further
investigate if APCCdh1 activity regulated PFKFB3 stability
upon glutamate receptor stimulation, neurons were trans-
fected with a green fluorescent protein (GFP)-PFKFB3
construct to visualize PFKFB3 subcellular localization by
confocal microscopy. PFKFB3 was mainly localized in the
nucleus of neurons, but glutamate treatment promoted its
accumulation, as revealed by the spread (nuclear plus
cytosolic) localization (Figures 2c and d). Interestingly, Cdh1
overexpression prevented this effect, suggesting that defi-
ciency in active Cdh1 was responsible for glutamate-mediated
PFKFB3 spreading (Figures 2c and d). Furthermore, expres-
sion of a GFP-PFKFB3 form with its KEN box mutated to
AAA (mut-PFKFB3), hence, insensitive to APCCdh1 activity,15
showed the spread-like localization, regardless of glutamate
treatment (Figures 2c and d). Thus, glutamate-mediated
PFKFB3 stabilization occurs via APCCdh1 inhibition.
To elucidate whether NMDAR-mediated PFKFB3 protein
stabilization had functional consequences for neuronal
metabolism, we assessed the rates of glycolysis and PPP,
as well as the glutathione redox status. The efficacy of a small
interfering RNA against PFKFB3 (siPFKFB3) to prevent
PFKFB3 protein accumulation was first tested. To do so,
primary neurons were transfected with the GFP-PFKFB3
complementary DNA (cDNA) construct, and PFKFB3 protein
was determined using an anti-flag (anti-GFP) antibody. As
shown in Figure 3a, PFKFB3 was accumulated 6 h after
Figure 1 Activation of NMDAR stabilizes PFKFB3 protein in neurons.
(a) Incubation of rat primary cortical neurons with glutamate (left panel) or NMDA
(right panel) increased the ratio of Fura-2-dependent fluorescence (at 510 nm) obtained
after excitation at 335/363 nm (F335/F363), indicating an increase in intracellular
Ca2þ . MK801 (10 mM) partially prevented glutamate-induced changes in F335/
F363 ratio and most of NMDA-dependent F335/F363 ratio changes. (b) Incubation
of neurons with glutamate (100mM/15 min) triggered time-dependent increase in
PFKFB3 protein, which was maximal after 6 h. (c) NMDA (100mM/15 min) mimicked
glutamate at increasing PFKFB3. (d) NMDA receptor antagonist, MK801 (10 mM),
prevented glutamate-mediated increase in PFKFB3. (e) Glutamate (100mM/15 min)
did not change PFKFB3 mRNA levels, as revealed by the unaltered intensity of the
predicted 300 bp band after reverse-transcription of total RNA samples, followed by
polymerase chain reaction (RT-PCR) using specific oligonucleotides for PFKFB3;
GAPDH (279 bp band) was used as loading control; the black/white inverted images
of the agarose gels are shown; w/o RT, RT-PCR for PFKFB3 without reverse
transcriptase
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Figure 2 Glutamate-mediated PFKFB3 stabilization occurs via Cdk5-mediated inhibition of APCCdh1 activity. (a) Glutamate treatment (100mM/15 min) increased, after
1 h, Cdk5-mediated H1 phosphorylation in rat primary cortical neurons; this effect was fully abolished by MK801 (10 mM). (b) Cdh1 is phosphorylated 6 h after glutamate
treatment (100mM/15 min), an effect that was prevented by MK801 (10 mM). (c) Confocal microscopy images of neurons transfected with GFP-PFKFB3 reveals its nuclear
localization. Glutamate promotes PFKFB3 accumulation, as revealed by its spread (nuclear plus cytosolic) localization; Cdh1 overexpression prevented this effect.
GFP-PFKFB3 mutated on its KEN box (KEN-AAA; mut-PFKFB3) showed the spread-like localization, regardless of glutamate treatment. (d) Percentage of neurons showing
nuclear or spread GFP-PFKFB3 localization in the experiments shown in c; these data were obtained by analyzingB30 neurons per condition per neuronal preparation
(n¼ 4). *Po0.05 versus the corresponding (nuclear or cytoplasmic) PFKFB3-none condition (ANOVA)
Figure 3 Glutamate stimulates PFKFB3-dependent increase in glycolysis, a decrease in PPP and promotes glutathione oxidation in neurons. (a) Incubation of
GFP-PFKFB3-expressing neurons with glutamate (100 mM/15 min) induced, 6 h after treatment, PFKFB3 accumulation in control, siRNA-treated neurons (siControl),
as revealed by an anti-GFP (Flag) antibody; transfection of neurons with an siPFKFB3 efficiently reduced PFKFB3 protein and prevented glutamate-induced PFKFB3
accumulation. (b) Incubation of neurons with glutamate (100mM/15 min) increased, after 6 h, the rate of glycolysis, as assessed by the determination of [3-3H]glucose
incorporation into 3H2O; this effect was abolished by preventing PFKFB3 accumulation in neurons previously transfected with siPFKFB3. (c) Glutamate treatment decreased,
after 6 h, the rate of the PPP, as assessed by the determination of the difference between 14CO2 produced by [1-
14C]glucose and that of [6-14C]glucose; this effect was
abolished by siPFKFB3. (d) Glutamate treatment did not change GSx (left panel), but it increased GSSG (middle panel) and the oxidized glutathione redox status (GSSG/GSx;
right panel); these effects were partially prevented by siPFKFB3. *Po0.05 versus none; #Po0.05 versus the corresponding siControl (ANOVA)
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glutamate (100 mM/15 min) incubation in control neurons
(siControl); however, transfection of neurons with an
siPFKFB3 decreased PFKFB3 protein abundance in control
neurons and prevented glutamate-mediated PFKFB3 accu-
mulation. We then assessed the rate of glycolysis, and we
found it to be significantly enhanced, after 6 h, by glutamate
treatment (Figure 3b); moreover, this was abolished by
preventing PFKFB3 accumulation using the siPFKFB3
(Figure 3b). In view that glycolysis and PPP are two
interconnected metabolic pathways, we then assessed
whether the increase in glycolysis altered glucose utilization
through the PPP. We found that glutamate treatment
decreased, after 6 h, the rate of PPP, an effect that was
abolished by siPFKFB3 (Figure 3c). Thus, glutamate triggers
a PFKFB3-dependent increase in glycolysis and decrease in
the PPP.
It has been previously shown that glucose metabolism
through the PPP is neuroprotective15,18,19 because of its
NADPH-regenerating function. Thus, NADPH is an essential
cofactor for glutathione regeneration, hence, the PPP
becomes necessary to prevent neuronal death by oxidative
stress.18 Thus, we next aimed to elucidate whether the
metabolic PPP/glycolytic shift triggered by glutamate treat-
ment induced oxidative stress. As shown in Figure 3d, total
glutathione (GSx) was unaltered, but its oxidized form
(GSSG) and the glutathione oxidized status (GSSG/GSx
ratio) significantly increased 6 h after glutamate treatment,
and these effects were prevented by siPFKFB3. To further
support evidence for oxidative stress, we next evaluated
whether a putative increased ROS production by glutamate
could be rescued by either knocking down a key glycolytic
enzyme, phosphoglucose isomerase (PGI), or by overexpres-
sing glucose-6-phosphate dehydrogenase (G6PD), the rate-
limiting enzyme of the PPP that we have previously shown to
be efficient in neurons.15,18 The efficacy of these tools were
first tested by western blotting (Figure 4a); thus, transfection
of neurons with the siRNA against PGI efficiently knocked
down PGI protein, whereas overexpression of the cDNA
encoding G6PD increased neuronal G6PD abundance.
Glutamate treatment (100 mM/15 min) increased, after 6 h,
neuronal ROS, an effect that was prevented by knocking
down PGI or PFKFB3, as it was by overexpressing G6PD, or
by blocking NMDAR with MK801 (Figure 4b). To assess
neuronal vulnerability to oxidative stress in this paradigm, we
then analyzed the proportion of annexin Vþ /7AAD neurons
(indicating neurons that had been targeted to apoptosis) after
glutamate treatment. We found that glutamate increased,
though modestly, apoptotic neuronal death via a mechanism
that could be prevented by silencing PGI or PFKFB3, as well
as by overexpressing G6PD or blocking NMDAR (Figure 4c).
Together, these results indicate that NMDAR activation
triggers oxidative stress and targets neurons for apoptotic
death by shifting PPP to glycolysis.
Finally, we sought to elucidate whether APCCdh1 activity
was responsible for PFKFB3-mediated oxidative stress and
neurodegeneration in excitotoxicity. As shown in Figure 5a,
glutamate increased ROS in neurons transfected with low
levels of wild-type PFKFB3 cDNA. However, transfection of
neurons with identical cDNA amounts of the KEN box-mutant
form of PFKFB3 (mut-PFKFB3) increased ROS to levels
similar to those triggered by glutamate; moreover, glutamate
did not further enhance ROS in neurons expressing mut-
PFKFB3 (Figure 5a). Interestingly, apoptotic death triggered
by glutamate in neurons transfected with PFKFB3 was
mimicked by mut-PFKFB3 (Figure 5b). Thus, expression of
APCCdh1-insensitive PFKFB3 mimics glutamate at causing
oxidative stress and neuronal death.
Figure 4 NMDAR activation triggers oxidative stress and apoptotic death by
switching PPP to glycolysis. (a) Transfection of neurons with an siRNA against PGI
(siPGI), efficiently knocked down PGI protein abundance (left panel). Transfection of
neurons with the full-length DNA encoding G6PD efficiently increased G6PD protein
abundance (right panel). (b) Glutamate treatment (100mM/15 min) increased ROS
in neurons, as assessed by MitoSox fluorescence by flow cytometry; this effect was
prevented by knocking down PGI (siPGI) or PFKFB3 (siPFKFB3), overexpressing
G6PD, or blocking NMDAR with MK801 (10mM). (c) Glutamate treatment increased
apoptotic neuronal death, as assessed by annexin Vþ /7-AAD fluorescence by
flow cytometry; this effect was prevented by silencing PGI (siPGI) or PFKFB3
(siPFKFB3), overexpressing G6PD or blocking NMDAR with MK801. *Po0.05
versus none; #Po0.05 versus siControl (glutamate; 5 104 events were acquired
in triplicate; results mean±S.E.M. from three independent neuronal preparations,
n¼ 3; ANOVA)
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Discussion
Neurons continuously degrade the glycolytic-promoting
enzyme PFKFB3 by APCCdh1 activity, and this allows a
considerable proportion of glucose to be oxidized via the
PPP, which functions as an antioxidant and survival metabolic
pathway.15 Here, we show that a short-term activation of
glutamate receptors in cortical neurons triggers delayed, time-
dependent PFKFB3 protein accumulation; the lack of change
in the PFKFB3 mRNA abundance ruled out a transcriptional
effect. Moreover, NMDA mimicked glutamate, and NMDAR
antagonist MK801 prevented PFKFB3 accumulation, indicat-
ing the direct involvement of NMDAR stimulation in PFKFB3
stabilization. Previously, it was reported that NMDAR stimula-
tion in cortical neurons promotes, in a Ca2þ -dependent
manner, p35 cleavage to p25 by calpain leading to Cdk5
activation.20 Here, we show that, under our experimental
culture conditions, rat primary cortical neurons efficiently
responded to NMDAR stimulation, as judged by the MK801-
inhibitable increased intracellular Ca2þ levels. Moreover, we
show that glutamate induced Cdk5 activation in a process that
was antagonized by MK801, indicating the involvement of
NMDAR. Given that NMDAR-mediated activation of Cdk5
phosphorylates Cdh1 leading to APCCdh1 inhibition,17 we
hypothesized that the stabilization of PFKFB3 could be
consequence of NMDAR-mediated APCCdh1 inhibition. In
good agreement with the presence of a nuclear-targeting
motif in PFKFB3,21 we found that expressed PFKFB3 was
localized in the nucleus, where neurons actively degraded it.
In addition, we show that Cdh1 was phosphorylated by
glutamate treatment, and that this was accompanied by
cellular spread of PFKFB3 from the nucleus to cytosol in a
Cdh1-inhibitable process; interestingly, the PFKFB3 mutant
form lacking the Cdh1-recognizing KEN motif spontaneously
accumulated. Together, these results indicate that PFKFB3
nuclear stabilization followed by cytosolic spread is the
consequence of APCCdh1 inhibition. The mechanism whereby
PFKFB3 is released from the nucleus remains unclear,
although the physiological significance is likely in view of the
cytoplasmic localization of the PFKFB3 target, 6-phospho-
fructo-1-kinase.
NMDAR-mediated PFKFB3 protein stabilization led to
increased PFKFB3 activity and efficiently upregulated the
rate of glycolysis in neurons. In previous studies, neurons
failed to upregulate glycolysis immediately after the bioener-
getic stress caused by mitochondrial inhibitors8,22 or NMDAR
activation.14 However, it should be noted that PFKFB3
stabilization takes place several hours after glutamate
treatment, thus explaining the absence of measurable short-
term glycolytic stimulation in cortical neurons in the previous
studies.8,14,22 Accordingly, the delayed increase in glycolysis
that we observe does not appear to be a neuronal attempt to
rapidly compensate for the mitochondrial energy dysfunction,
which occurs immediately after NMDAR stimulation.7 Instead,
the delayed glycolysis activation reflects a long-term meta-
bolic adaptation of neurons by excitotoxic insult; however,
such an adaptation concurs with concomitant decrease in the
rate of glucose oxidation through the PPP, hence, triggering
oxidative stress and neurotoxicity. Intriguingly, although the
stimulation of glycolysis is cytotoxic in neurons, it is
cytoprotective in astrocytes.8 This different outcome shown
by neurons and astrocytes is consistent with the expression of
a robust antioxidant system in astrocytes that is not present in
neurons.23 Upon inhibition of mitochondrial respiration,
astrocytes switch on glycolysis, via the 50-AMP-activated
protein kinase-PFKFB3 pathway,14 to compensate for the
ATP deficiency without affecting their antioxidant status.24
However, shifting glucose utilization from PPP to glycolysis in
neurons compromises the efficacy of the critical antioxidant
NADPH-glutathione regenerating system, hence causing
delayed neurotoxicity. Importantly, both the increase in
glycolysis and the decrease in PPP could be fully abolished
by siPFKFB3, indicating that both metabolic pathways are
wholly controlled by PFKFB3. In this context, it should be
mentioned that Tp53-inducible glycolysis and apoptosis
regulator (TIGAR), by catalyzing F2,6P2 degradation inhibits
glycolysis and stimulates PPP.25 Thus, the control over
F2,6P2 concentrations by either PFKFB3 – with a main
fructose-6-phosphate-2-kinase activity12,13 – or TIGAR – with
fructose-2,6-bisphosphatase activity25 – appears to deter-
mine the fate of glucose metabolism. However, no evidence
for NMDAR-mediated p53 upregulation is currently available,
hence, remaining elusive whether TIGAR induction has a
determinant role in neuronal metabolic change upon NMDAR
stimulation.
The metabolic PPP to glycolysis shift triggered by NMDAR
stimulation was accompanied by oxidative stress, as revealed
both by an increase in the oxidized glutathione redox status
and by the increased mitochondrial ROS, as well as apoptotic
neuronal death. These data contrast with those reporting that
NMDAR-mediated increase in neuronal ROS could be
blocked with 6-aminonicotinamide, an inhibitor of PPP that
produces NADPH required for NADPH oxidase activity.6
Whether the different neuronal settings (defined versus
Figure 5 Expression of APCCdh1-insensitive PFKFB3 mimics glutamate at
causing oxidative stress and neuronal death. (a) Glutamate treatment (100mM/
15 min) increased ROS in neurons transfected with low levels of wild-type PFKFB3
cDNA; transfection of neurons with identical cDNA amounts of the KEN box-mut-
PFKFB3 increased ROS to similar levels to those triggered by glutamate; glutamate
did not further enhance ROS in neurons expressing mut-PFKFB3. (b) Glutamate
increased apoptotic death of neurons transfected with low levels of PFKFB3 cDNA;
transfection of neurons with identical cDNA amounts of mut-PFKFB3 increased
apoptotic death to similar levels to those triggered by glutamate; glutamate did not
further enhance apoptotic death in neurons expressing mut-PFKFB3. *Po0.05
versus none (PFKFB3; 3 104 events were acquired in triplicate; results
mean±S.E.M. from three independent neuronal preparations, n¼ 3; ANOVA)
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serum-based media) or the types of tools used (pharmaco-
logical versus genetic approaches to modulate glycolysis and
PPP) are responsible for this apparent controversy remains
elusive. However, in our hands, silencing PFKFB3 or PGI,
which effectively inhibited glycolysis,15 or G6PD overexpres-
sion, a potent activator of the PPP,18 prevented such a
metabolic switch and the concomitant ROS production by
NMDAR stimulation. In fact, PPP activity produces reduced
equivalents in the form of NADPH,26 which is also a necessary
cofactor for antioxidant glutathione regeneration.18 Thus,
PFKFB3 silencing significantly prevented the increase in
oxidized glutathione status caused by NMDAR stimulation
and this was critical at determining neuronal survival.
Interestingly, it has been shown that, when oxidized,
cytochrome c is released from mitochondria, hence promoting
apoptotic neuronal death, and that PPP activity is essential at
maintaining cytochrome c reduced.27 Our results, showing
oxidative stress and neurodegeneration following PFKFB3
stabilization by NMDAR stimulation, confirm the critical role of
PPP at regulating neuronal apoptosis. Furthermore, they
show that the loss of PPP activity by APCCdh1 inhibition is a
novel and important player in excitotoxicity. Together, these
findings highlight the importance of metabolic modulation in
excitotoxicity and neurodegeneration and emphasize that
metabolic targets should be considered when designing
therapeutic strategies.
Materials and Methods
Plasmid constructions and site-directed mutagenesis. The rat
PFKFB3 full-length cDNA (splice variant K6; 1563 bp; accession number
BAA21754) was obtained, by reverse-transcriptase polymerase chain reaction
(RT-PCR), at our laboratory.15 PFKFB3 cDNA was fused, at its 50-terminus, with
the full-length cDNA encoding the GFP and subcloned in pCDNA3.0 vector.
This GFP-PFKFB3 cDNA fusion construct was then subjected to site-directed
mutagenesis of its KEN-box to AAA using the QuikChange XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) using the following forward and
reverse primers, respectively: 50-ATCCTTCATTTTGCCGCAGCAGCTGACTTCAA
GGC-30 and 50-ATGCCTTGAAGTCAGCTGCTGCGGCAAAATGAAGG-30 (mutated
nucleotides underlined). Human full-length Cdh1 cDNA (accession number
NM_016263) was a generous gift of Dr. J Pines (Gurdon Institute, University of
Cambridge, UK).
RNA interference. To knockdown PGI (accession number NM_207192),
we used the following sequence for siRNA: 50-CCTTACCAGACGTAGTGTT-30
(nt 1248–1266). To knockdown PFKFB3 we used the sequence 50-AAAGCCTC
GCATCAACAGC-30 (nt 1908–1926). Both siRNAs were previously validated at our
laboratory for efficacy.14,15 An siRNA against luciferase (50-CTGACGCGGAATAC
TTCGATT-30) was used as control.
RT-PCR analysis. Total RNA was purified from neurons using a commercially
available kit (Sigma, Saint Louis, MO, USA). PFKFB3 mRNA expression was
analyzed by 4.5% agarose electrophoresis after RT-PCR using the following
forward and reverse oligonucleotides, respectively: 50-CCAGCCTCTTGACCCT
GATAAATG-30 and 50-TCCACACGCGGAGGTCCTTCAGAT-30 for PFKFB3, and
50-CTGGCGTCTTCACCACCAT-30 and 50-AGGGGCCATCCACAGTCTT-30 for
GAPDH. Reverse transcription was performed at 48 1C for 50 min, and PCR
conditions were 10 min at 95 1C, 35 cycles of 1 min at 95 1C, 1 min at 58 1C and
30 s at 68 1C. Final extension was carried out for 10 min at 72 1C. In no case was
a band detected by PCR without reverse transcription.
Antibodies. An anti-PFKFB3 (K3-K6 splice variants) antibody was generated,
by rabbit immunization with the synthetic peptide 508MRSPRSGAESSQKH521-C, at
our laboratory as previously described.15 A commercial anti-PFKFB3 antibody
raised against a C-terminal region of the human PFKFB3 (protein accession
Q16875; catalog number H00005209-M08, Novus Biologicals, Cambridge, UK)
was also used; this antibody cross-reacts with human and rat PFKFB3, thus
recognizing a region that is shared by all translational products of the rat K1 to
K8 PFKFB3 mRNA splice variants. Anti-Cdh1 (AR38) was a generous gift from
J Gannon (Clare Hall Laboratories, Cancer Research, UK). Anti-Cdk5 (C-8) and
anti-PGI (K-16) were from Santa Cruz Biotechnology (Heidelberg, Germany).
Anti-GFP was purchased from Abcam (Cambridge Science Park, Cambridge, UK).
Anti-G6PD and anti-GAPDH were purchased from Sigma, and anti-phosphoserine
from Zymed (Invitrogen, Groningen, The Netherlands).
Cell cultures. Cortical neurons in primary culture were prepared from fetal
(E16) Wistar rats. Cells were seeded (2.5 105 cells/cm2) in DMEM (Sigma)
supplemented with 10% (v/v) fetal calf serum (Roche Diagnostics, Heidelberg,
Germany) and incubated at 37 1C in a humidified 5% CO2-containing atmosphere.
After 48 h of plating, the medium was replaced with DMEM supplemented with 5%
horse serum (Sigma) and with 20 mM D-glucose. On day 4, cytosine arabinoside
(10mM) was added in order to prevent non-neuronal proliferation. Cells were used
by day 6, when enrichment wasB99% (neurofilament; data not shown).
Cell treatments. Transfection of cells with plasmid vectors was carried out
using 0.16–1.6mg/ml of the plasmids, as indicated in the figure legends. All
transfections were performed using lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions, at day 5 in vitro. After 6 h, the medium was removed
and cells were further incubated overnight in the presence of culture medium. For
RNA interference experiments, siRNAs (purchased from Thermo Fisher Scientific,
Lafayette, CO, USA; sequences described above) were used. In dose-response
preliminary settings, primary neurons were transfected, using Lipofectamine 2000
with 20–100 nM of the siRNAs, which showed a dose-dependent effect; only the
results using 100 nM are shown. siRNA transfections were performed at day 3 in vitro
and experiments were performed at day 6, when an efficient knockdown of the target
proteins was obtained. For NMDAR activation, neurons at 6 days in vitro were
incubated with 100mM glutamate (plus 10mM glycine) or 100mM NMDA (plus 10mM
glycine) in buffered Hanks’ solution (pH 7.4) for 15 min.7 When indicated, incubations
were performed in the presence of MK-801 (10mM; Sigma). Neurons were then
washed and further incubated in culture medium for the indicated time period.
Flow cytometric analysis of apoptotic cell death. APC/C-conjugated
annexin-V and 7-aminoactinomycin D (7-AAD) (Becton Dickinson Biosciences,
San Jose, CA, USA) were used to determine quantitatively the percentage of
apoptotic neurons by flow cytometry. Cells were stained with annexin V-APC
and 7-AAD, following the manufacturer’s instructions, and were analyzed on a
FACScalibur flow cytometer (15 mW argon ion laser tuned at 488 nm) using the
CellQuest software software (BDB). Both GFPþ and GFP cells were analyzed
separately and the annexin V-APC-stained cells that were 7-AAD-negative were
considered to be apoptotic.15
Detection of ROS. This was carried out using MitoSox-Red (Invitrogen).
Neurons were incubated with 2 mM MitoSox-Red for 30 min, washed with PBS and
the fluorescence assessed by flow cytometry.15
Measurement of the glycolytic and PPP fluxes. Suspensions of
known amounts of cells (4–5 105 cells) obtained by smooth detaching from the
cultures 6 h after glutamate treatments, were incubated in sealed vials containing a
central well, which was used for 14CO2 or
3H2O trapping. Cells were incubated in the
presence of 1mCi of either D-[1-14C] glucose or D-[6-14C] glucose for PPP
determinations, whereas 5mCi of D-[3-3H] glucose were used for glycolytic flux
determinations, both in a Krebs–Henseleit buffer (11 mM Na2HPO4, 122 mM NaCl,
3.1 mM KCl, 0.4 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM CaCl2; pH 7.4) containing
5 mM D-glucose at 37 1C. In order to ensure an adequate O2 supply for oxidative
metabolism by the cells throughout the 90 min incubation period, the gas phase in
the vials containing the cells was supplied with extra O2 before the vials were
sealed. The glycolytic flux was measured by assaying the rate of 3H2O production
from [3-3H]glucose, as detailed previously.15 The PPP flux was measured by
assessing the difference between 14CO2 production from [1-
14C]glucose – which
decarboxylates via the 6-phosphogluconate dehydrogenase-catalyzed reaction –
and that of [6-14C]glucose – which decarboxylates via the tricarboxylic acid cycle.18,28
Glutathionemeasurements. For glutathione determinations, neurons were
treated with 1% (w/v) sulfosalicylic acid and centrifuged at 13 000 g for 5 min
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at 4 1C. GSx (the amount of reduced glutathione (GSH), plus two times the amount
of oxidized glutathione (GSSG)) and GSSG concentrations were measured in the
supernatants using the enzymatic method of Tietze.29 GSSG was quantified after
derivatization of GSH in the samples with 2-vinylpyridine. Data were extrapolated to
those obtained with GSSG standards (0–5mM for GSSG; 0–50mM for GSx). The
glutathione redox status was expressed as the GSSG/GSx ratio, as previously
described.18,30
Fura-2 fluorescencemeasurements. To estimate the intracellular Ca2þ -
dependent changes by NMDAR stimulation in cortical neurons we used the
fluorescent probe Fura-2 (acetoxymethyl-derivative; Life Technologies, Eugene,
OR, USA), as previously described.31 Essentially, neurons at 6 days in vitro, seeded
in 96-well plates (Nunc), were incubated with Fura-2 (2 mM; dissolved in dimethyl
sulphoxide (DMSO)) for 40 min in DMEM at 37 1C. Then, cells were washed and
further incubated with standard buffer (140 mM NaCl, 2.5 mM KCl, 15 mM Tris-HCl,
5 mM D-glucose, 1.2 mM Na2HPO4, 1 mM MgSO4 and 1 mM CaCl2, pH 7.4) for
30 min and 37 1C. Finally, the standard buffer was removed and experimental
buffer (140 mM NaCl, 2.5 mM KCl, 15 mM Tris-HCl, D-glucose, 1.2 mM Na2HPO4,
and 2 mM CaCl2, pH 7.4), either in the absence or in the presence of MK801
(10mM), was added. Emissions at 510 nm, after excitations at 335 and 363 nm,
respectively, were recorded at 1 s intervals in a Varioskan Flash (Thermo Fischer,
Vantaa, Finland) spectrofluorometer at 32 1C. AfterB10 s, glutamate (100mM) or
NMDA (100mM) (plus 10mM glycine) was injected and emissions were further
recorded for 50 s. Ca2þ -dependent fluorescence changes were estimated by
representing the ratio of fluorescence emitted at 510 nm obtained after excitation
at 335 nm divided by that at 363 nm (F335/F363). Background subtraction was
accomplished from emission values obtained in Fura-2-lacking (DMSO-containing)
neurons. In preliminary experiments, the Ca2þ specificity of the measurements
was tested in Ca2þ -free experimental buffer containing 1 mM ethylene glycol
tetraacetic acid (EGTA), which fully prevented the changes in 510 nm emissions
(data not shown). At least, six wells were recorded per condition in each experiment
(n¼ 4 experiments) and the averaged values are shown.
Western blot analysis. After transfections and treatments, neurons were
lysed in RIPA buffer (2% sodium dodecylsulphate, 2 mM ethylene diamine tetraacetic
acid (EDTA), 2 mM EGTA, 50 mM Tris; pH 7.5), supplemented with phosphatase
inhibitors (1 mM Na3VO4, 50 mM NaF) and protease inhibitors (100mM phenyl-
methylsulfonyl fluoride, 50mg/ml anti-papain, 50mg/ml pepstatin, 50mg/ml amastatin,
50mg/ml leupeptin, 50mg/ml bestatin and 50mg/ml soybean trypsin inhibitor) and
boiled for 5 min. Aliquots of cell extracts were subjected to sodium dodecyl sulfate
(SDS) polyacrylamide gel (MiniProtean, Bio-Rad, Hercules, CA, USA) and blotted with
antibodies overnight at 4 1C. Signal detection was performed with an enhanced
chemiluminescence kit (Pierce, Thermo Scientific, Waltham, MA, USA).
Immunoprecipitation and Cdk5 kinase activity. Neurons were lysed
in ice-cold buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM EDTA,
2 mM EGTA, 1% NP-40, supplemented with the phosphatase and protease
inhibitors cited above. Cell extracts were clarified by centrifugation and supernatants
(50mg of protein for immunoprecipitation experiments, 500mg for Cdk5 kinase
assays) were incubated with anti-Cdh1 or anti-Cdk5, overnight at 4 1C, followed by
the addition of 15–30ml of protein A-sepharose (GE Healthcare Life Sciences,
Uppsala, Sweden) for 1–2 h at 4 1C. Immunoprecipitates were extensively washed
with lysis buffer and either detected by western blot analysis against anti-
phosphoserine or resuspended in kinase buffer (20 mM Tris-HCl pH 7.6,
20 mM MgCl2, 2 mM MnCl2, 1 mM EDTA, 1 mM EGTA, 0.1 mM dithiothreitol)
containing 20mM ATP, 10mCi of [g-32P]ATP and histone-H1 (50mg/ml; Sigma)
for SDS-polyacrylamide gel (12%) electrophoresis; transferred proteins were
visualized by autoradiography and anti-Cdk5 blotting.32
Protein determinations. Protein concentrations were determined in the cell
suspensions, lysates or in parallel cell culture incubations after solubilization with
0.1 M NaOH. Protein concentrations were determined as described33 using bovine
serum albumin as a standard.
Confocal microscopy. Neurons were grown on glass coverslips. After
transfections and treatments they were fixed with 4% (v/v in PBS) paraformaldehyde
for 20 min and incubated with DAPI (30mM; Sigma). Confocal microscopy images
were obtained with a Leica SP5 microscope (DMI-6000B model; Leica Microsystems
GmbH, Wetzlar, Germany).
Statistical analysis. Measurements from individual cultures were always
carried out in triplicate. The results are expressed as mean±S.E.M. values for
three different culture preparations. Statistical analysis of the results was performed
by one-way analysis of variance (ANOVA), followed by the least significant
difference multiple range test. In all cases, Po0.05 was considered significant.
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